

Partnership. Innovation. Passion.

February 14, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322 Ref: Scrip Name: GLS

Dear Sir/Madam,

Sub:- Monitoring Agency Report for the Quarter ended 31st December, 2021

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 31st December, 2021 in respect of utilization of proceeds of the IPO of the Company.


This is for your information and record.

Thanking you

Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary & Compliance Officer

Encl: As above



CIN: L65920MH1994PLC080618 Website: www.hdfcbank.com HDFC Bank Limited, CMS - Disbursement Team, Lodha - I Think Techno Campus, Office Floor 3, Opposite Crompton Greaves Limited, Next to Kanjurmarg Railway Station, Kanjurmarg East, Mumbai - 400 042

SCHEDULE IX

MONITORING REPORT

NAME OF THE MONITORING AGENCY: HDFC Bank Limited

MONITORING REPORT FOR THE QUARTER ENDED: December 2021

Name of the Issuer: Glenmark Life Sciences Limited

(a) Deviation from the objects: Not Applicable

(b) Range of Deviation: Not applicable

Declaration:

4

We hereby declare that this report is based on the format as prescribed by SEBI (ICDR) Regulation ,2018, as amended. I/We further declare basis the certification issued by the statutory auditor of the company that this report provides true and fair view of the utilization of issue proceeds.

We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer.

Signature: 1.1. Govern

Name of the Authorized Person/Signing Authority: Tushar Gavankar

Designation of Authorized person/Signing Authority: Deputy Vice President

Seal of the Monitoring Agency:

Date: 14.02.2022



1) Issuer Details:

Name of the issuer : Glenmark Life Sciences Limited

The names of the promoters of the issuer : Glenmark Pharmaceuticals Limited

Industry/sector to which it belongs : Pharmaceutical

2) Issue Details:

Issue Period : 27th July, 2021 – 29th July, 2020

Type of issue [public/rights] : Public issue
Type of specified securities : Equity Shares

Issue size (in Millions) : Fresh issue of Rs. 15,136 million

3) Details of the arrangement made to ensure the monitoring of issue proceeds

Particulars	Reply	Comments of Statutory Auditor Comments (if any)	Comments of the Monitoring Agency
Whether all the utilization is as per disclosure in	Yes/Ne	a galastine, p. p. poles (Galastine)	stight statistic has been been
Offer Document?		Yes	Yes
Whether Shareholder approval is obtained in case of material deviations# from expenditures disclosed in Offer Document?	Yes/No	NA	NA NA
Whether means of finance for disclosed objects of the Issue has changed?	Yes/ No	No	NA
Any major deviation observed over the earlier monitoring agency reports?	Yes/ No	No -	NA
Whether all Government / Statutory approvals related to the object(s) obtained?	Yes/No	NA	NA
Whether all arrangements pertaining to technical assistance/collaboration in operation?	Yes/No	NA	NA .
Any favourable events improving object(s) viability	Yes /No	No	NA
Any unfavourable events affecting object(s) viability	Yes /No	No	NA
Any other relevant information that may materially affect the decision making of the Investors	Yes /No	No	NA NA

Where material deviation may be defined to mean:

a) Deviation in the objects or purposes for which the funds have been raised;

b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

4) Details of object(s)s to be monitored:

i. Cost of object(s)-

(i) Cost of objects- Particulars	Estimated amount (Rupees in Million)		
Gross proceeds from the Fresh Issue	10,600.00		
(Less) Fresh Issue expenses*	(577.96)		
Net Proceeds of the Fresh Issue (the "Net Proceeds")	10,022.04		

*Represents company's share of offer expenses.

Particulars	Original Cost (as per Offer Document) (Rupees in Million)	Revised Cost (Rupees in Million)	Comments of Statutory Auditor Comments (if any)
Gross Proceeds from the Fresh Issue	10,104.09	10,022.04	The revision in General corporate purposes expense is on account of reduction in GST and
			other minor expenses as compared to estimated.

ii. Progress in the object(s)

(Rupees in Million) **Amount Utilised** As at During At the Sr. Net **Total Unutilised** Beginnin Item Head The end of No **Proceeds** Amount g of the Quarter Quarter Quarter Payment of outstanding 1 purchase consideration to the 8,000.00 8,000.00 8,000.00 NIL Promoter Funding the capital 2 1,527.64 75.14 252.13 327.27 1200.37 expenditure requirements General Corporate Purposes 476.27 494.40 476.27 18.13

8,551.41

252.13

8,803.54

1,218.50

10,022.04



Total

iii. Deployment of unutilized Issue proceeds:

(INR in Million)

_	(INR in million)	Type of	_Amount	Maturity date	ROI	Book value as at	
	Sr. No.	instrument and name of the entity invested in	invested			31 Dec 21	1
	1 527	Monitoring agency account	38.50	NA	NA	38.50	
-	2	Fixed deposit –	1,180.00	03-Jan-22	3.25%	1,180.00	
1.7		India	43 90				
					Total	1,218.50	

i. Delay in implementation of the object(s) -

Object(s) Name	Completion Date		Delay (No. of days/	Comments of Statutory
	As per Offer Document	Actual *	months) Auditor Comments (if any	Auditor Comments (if any)
NIL	NIL	NIL	NIL	NIL

^{*} In case of continuing object(s) please specify latest/revised estimate of completion date.

